ClinicalTrials.gg

Brain Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,441 studies for Brain Neoplasms across more than 10 countries. 541 are recruiting or about to start. 1,203 of them are mainly about Brain Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 9 narrower conditions too, such as Pituitary Neoplasms: 2,893 studies, 657 open.

ClinicalTrials.gov finds 4,501 studies for Brain Neoplasms. How that becomes 2,441 here

This page counts the studies the registry files under Brain Neoplasms, and those it files under no condition that list Brain Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 4,501Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −386Filed under a narrower condition, counted on its own pagePituitary Neoplasms 174 · Diffuse Intrinsic Pontine Glioma 86 · Choroid Plexus Neoplasms 57 · Infratentorial Neoplasms 19 · Pinealoma 17 · Prolactinoma 15 · 3 more
  3. −81List Brain Neoplasms as a condition, but the registry did not file them under itMost often written as “Brain Tumor Adult” (14), “Pediatric Brain Tumor” (10), and “Childhood Brain Tumor” (9). The registry filed them under other conditions only, most often Neoplasms (18) and Glioma (12).
  4. −1,598Match it another way283 name it in the title, 30 in a keyword, and 1,285 by a synonym or other text the search reads.
  5. 2,436Counted here and found by its search64 of them list Brain Neoplasms in their own words; the registry filed them under no condition.
  6. +5
    Counted here, but its search does not find them
  7. 2,441The count on this page

Status

Completed
1,098
Recruiting
425
Terminated
285
Status unknown
219
Active, not recruiting
176
Withdrawn
107

Phase

Phase 2
798
Phase 1
601
Phase 3
154
Early Phase 1
66
Phase 4
36

Where

United States
1,443
Canada
180
China
179
France
172
Germany
104
Italy
95

Who develops what

Add Brain Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 20 programs from 19 companies, 8 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Telix Pharmaceuticals, BioNTech and Bristol-Myers Squibb here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TemozolomideRecent, repeated
Evidence
  • NCT07569042 · Novelwise Pharmaceutical Corporation · Phase 2 · live · background · “Temozolomide” · registered Apr 2026
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Temozolomide” · registered Mar 2026
  • NCT07326566 · Black Diamond Therapeutics, Inc. · Phase 2 · live · comparator · “temozolomide (TMZ)” · registered Jan 2026
  • NCT07297212 · BioNTech SE · Phase 2 · live · background · “Temozolomide” · registered Dec 2025
  • NCT06413706 · Eli Lilly and Company · Phase 2 · live · background · “Temozolomide” · registered May 2024
Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized56 studies
BevacizumabRecent, repeated
Evidence
  • NCT07297212 · BioNTech SE · Phase 2 · live · comparator · “Bevacizumab” · registered Dec 2025
  • NCT06496971 · NaviFUS Corporation · Phase 3 · live · background · “Bevacizumab” · registered Jul 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
  • NCT03149003 · Sumitomo Pharma Co., Ltd. · Phase 3 · background · “Bevacizumab” · registered May 2017
  • NCT02330562 · Bristol-Myers Squibb · Phase 2 · background · “BEV” · registered Dec 2014
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others33 studies
pembrolizumabRecent, repeated
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
  • NCT05317858 · insightec · Phase 3 · live · background · “Pembrolizumab” · registered Mar 2022
  • NCT04479241 · Istari Oncology, Inc. · Phase 2 · background · “pembrolizumab” · registered Jul 2020
  • NCT04121455 · TME Pharma AG · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2019
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)22 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Mar 2026
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
  • NCT04538742 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Aug 2020
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed22 studies
osimertinibRecent, repeated
Evidence
  • NCT07206498 · Wayshine Biopharm, Inc. · Phase 2 · live · background · “Osimertinib (Tagrisso®)” · registered Sep 2025
  • NCT05948813 · TYK Medicines, Inc · Phase 2 · live · comparator · “Osimertinib” · registered Jul 2023
AstraZeneca93% of its industry studiesUS: AstraZeneca (FDA 2015)EU: AstraZeneca (EMA 2016)22 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
Eli Lilly and Company16% of its industry studies22 studies
NivolumabRecent, repeated
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
  • NCT05317858 · insightec · Phase 3 · live · background · “Nivolumab” · registered Mar 2022
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)22 studies

16 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Floretyrosine F 18 ([18F]FET)☆ Track1 live phase-3 study: NCT07931261Telix Pharmaceuticals Limited

The 1 in phase 3 with the nearest primary completion, of 20 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 15 Jan 2027 est.desoxyepothilone B · Biostar Pharma, Inc. · Phase 2 named, not the main aimNCT06764940 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases — primary endpoint: Intracranial Objective Response Rate (IC-ORR) evaluated by investigator according to RECIST 1.1 criteria. · 120 enrolled
  • 31 Mar 2027 est.PRMT5 Inhibitor TNG456 · Tango Therapeutics, Inc. · Phase 2 named, not the main aimstudied with abemaciclibNCT06810544 Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss — primary endpoint: Phase 1 Maximum Tolerated Dose · 191 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Brain Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 25 open · Immune checkpoint inhibitors 16 open · Antibody-drug conjugates (ADCs) 9 open · Alkylating agents 8 open · Antimetabolites 7 open

Coming up

238studies finish main data collection within a year15 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger. 80 (19%) take children under 18. 8 (2%) are for women only and 1 (<1%) for men only; 36 (8%) take healthy volunteers.

Recruiting studies that take each age, of 425
AgeWomenMen
1071 (17%)71 (17%)
18401 (94%)395 (93%)
30383 (90%)376 (88%)
40374 (88%)367 (86%)
50372 (88%)365 (86%)
65369 (87%)362 (85%)
75354 (83%)348 (82%)
85317 (75%)312 (73%)

Across all 2,441 studies, recruiting or not: 22% stop at 75 or younger and 15% at 65; 21% take children; 2% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Brain Neoplasms studies take

Of 252 phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 61 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 154 mo36–84 · 205 studies—56 mo36–84 · 176 studies
Phase 1/282 mo48–105 · 72 studies—85 mo50–105 · 50 studies
Phase 261 mo38–98 · 252 studies43 mo24–55 · 44 studies67 mo43–100 · 208 studies
Phase 381 mo48–269 · 56 studies——
Interventional, no phase64 mo35–125 · 317 studies—65 mo36–126 · 306 studies
Observational82 mo41–269 · 200 studies—82 mo42–269 · 182 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 2,441. Browse all 2,441 → or search them.